Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support

Journal of the National Cancer Institute

Volumn 88, Issue 19, 1996, Pages 1393-1398

  De Wit, Ronald ^a   Verweij, Jaap ^a   Bontenbal, Marijke ^a   Kruit, Wim H J ^a   Seynaeve, Caroline ^a   Schmitz, Paul I M ^a   Stoter, Gerrit ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

EID: 0029768738     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.19.1393     Document Type: Article

References (26)

1. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med 1992;327:28-35, 99-106.
2. Duhrsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988;72:2074-81.
3. Molineux G, Pojda Z, Hampson IN, Lord BI, Dexter TM. Transplantation potential of peripheral blood stem cells induced by granulocyte colony-stimulating factor. Blood 1990; 76:2153-8.
4. Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D, et al. Effect of peripheralblood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy [see comment citations in Medline]. Lancet 1992;339:640-4.
5. Vadhan-Raj S, Broxmeyer HE, Hittelman WN, Papadopoulos NE, Chawla SP, Fenoglio C, et al. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level. J Clin Oncol 1992;10: 1266-77.
6. Brugger W, Bross K, Frisch J, Dem P. Weber B, Mertelsmann R, et al. Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin [see comment citation in Medline]. Blood 1992;79:1193-200.
7. Elias AD, Ayash L, Anderson KC, Hunt M, Wheeler C, Schwartz G, et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 1992;79:3036-44.
8. Crown J, Kritz A, Vahdat L, Reich L, Moore M, Hamilton N, et al. Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer. J Clin Oncol 1993;11:1144-9.
9. Janik J, Miller L, Smith J, Kopp W, Alvord G, Gause B, et al. Prechemotherapy granulocyte-macrophage colony stimulating factor (GMCSF) prevents topotecan-induced neutropenia. Proc ASCO 1993;12:437.
10. Aglietta M, Monzeglio C, Pasquino P, Carnino F, Stern AC, Gavosto F. Short-term administration of granulocyte-macrophage colony stimulating factor decreases hematopoietic toxicity of cytostatic drugs. Cancer 1993;72: 2970-3.
11. Hoekman K, Wagstaff J, van Groeningen CJ, Vermerken JB, Boven E, Pinedo HM. Effects of recombinant human granulocyte-macrophage colony-stimulating factor on myelosuppression induced by multiple cycles of high-dose chemotherapy in patients with advanced breast cancer. J Natl Cancer Inst 1991; 83:1546-53.
12. Richel DJ, Vlasveld LT, Wijngaarden MJ, Van der School E, Schornagel JK, Somers R, et al. Peripheral blood stem cell (PBSC) mobilization and transplantation (PSCT) in patients with malignant lymphomas and solid tumours [abstract]. Blood 1992;80:927.
13. Beahrs OE, Henson DE, Hutter RV, Myers MH. Manual for staging of cancer. 4th ed. Philadelphia: Lippincott, 1992.
14. Dreger P, Haferlach T, Eckstein V, Jacobs S, Suttorp M, Loffler H, et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol 1994;87:609-13.
15. Pocock SJ. Aspects of data analysis. In: Pocock SJ, editor. Clinical trials. New York: John Wiley & Sons, 1983:220-1.
16. Broxmeyer HE, Benninger L, Patel SR, Benjamin RS, Vadhan-Raj S. Kinetic response of human marrow myeloid progenitor cells to in vivo treatment of patients with granulocyte colony-stimulating factor is different from the response to treatment with granulocyte-macrophage colony-stimulating factor. Exp Hematol 1994;22:100-2.
17. Gabrilove JL, Jakubowski A, Scher J, Stemberg C, Wong G, Grous J, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to the chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988;318:1414-22.
18. Seidman AD, Scher HI, Gabrilove JL, Bajorin DF, Motzer FJ, O'Dell M, et al. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer [see comment citation in Medline]. J Clin Oncol 1993;11:408-14.
19. Bronchud MH, Howell A, Crowther D, Hopwood P, Souza L, Dexter TM. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 1989;60:121-5.
20. Kehoe S, Poole CJ, Stanley A, Earl HM, Blackledge GR. A phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in the intensification of cisplatin and cyclophosphamide chemotherapy for advanced ovarian cancer. Br J Cancer 1994;69:537-40.
21. Pettengell R, Gurney H, Radford JA, Daekin DP, James R, Wilkinson PM. et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992;80:1430-6.
22. Crown J, Kritz A, Vahdat L, Reich L, Moore M, Hamilton N, et al. Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer. J Clin Oncol 1993;11:1144-9.
23. Piccart MJ, Bruning P, Wildiers J, Awada A, Schomagel JH, Thomas J. An EORTC pilot study of filgrastim (recombinant human granulocyte colony-stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer. Ann Oncol 1995;6: 673-7.
24. Fossa SD, Kaye SB, Mead GM, Cullen M, de Wit R, Bodrogi I. An MRC/EORTC randomised trial in poor prognosis metastatic teratoma comparing treatment with/without filgrastim (G-CSF). Proc ASCO 1995;14: 245.
25. Pettengell R, Woll PJ, Thatcher N, Dexter TM, Testa NG. Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood. J Clin Oncol 1995;13:148-56.
26. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidencebased, clinical practice guidelines. J Clin Oncol 1994;12:2471-508.